Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac
Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a 40m joint venture to fight Antimicrobial Resistance (AMR).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
/in News/by Thomas GabrielczykFrench drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences drug vibegron for the treatment of overactive bladder in Europe.
CureVac NV sues BioNTech for IP infringement
/in News/by Thomas GabrielczykGerman mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.
French Ipsen falls after Epizyme take-over announcement
/in News/by Thomas GabrielczykShares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.
TWB announces winners in industrial biotech start-up contest
/in News/by Thomas GabrielczykAt the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth 50,000.
BIONTech breaks ground for manufacturing site in Rwanda
/in News/by Thomas GabrielczykBioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this years end toKigall.
Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
/in News/by Thomas GabrielczykIn an effort to become a major player in Europes growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.
French ImCheck get´s a USD103m check by Pfizer and a pack of VCs
/in News/by Thomas GabrielczykImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, […]
$50m for London CHARM Therapeutics for deep minded folding expertise
/in News/by Thomas GabrielczykCHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.
Biotalys first proteinbased biocontrol shows up in vineyards
/in News/by Thomas GabrielczykBased on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch […]